Unite.AI is committed to rigorous editorial standards. We may receive compensation when you click on links to products we review. Please view our affiliate disclosure. Technological innovation has ...
The company's CEO, James Dentzer, expressed optimism about the progress of Curis's clinical programs and the ... emavusertib. In terms of analyst ratings, H.C. Wainwright adjusted its outlook ...
Yaron Werber has given his Buy rating due to a combination of factors, primarily the promising progress and outcomes of IO Biotech’s clinical trials. The company’s Phase 3 melanoma study is on ...
Notes payable, plus accrued interest, totaled approximately $6.9 million. The current portion of the notes payable plus accrued interest totaled approximately $3.7 million. Included in the current ...
The company reported a strong cash position, which is expected to fund operations into late 2026, and emphasized the progress made in its clinical programs, including the completion of enrollment ...